MONTE ROSA THERAPEUTICS INC's ticker is GLUE and the CUSIP is 61225M102. A total of 73 filers reported holding MONTE ROSA THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $50,310 | +1267.1% | 13,452 | +2477.0% | 0.00% | – |
| Q1 2024 | $3,680 | -91.6% | 522 | -93.3% | 0.00% | -100.0% |
| Q4 2023 | $44,048 | -46.4% | 7,796 | -54.6% | 0.00% | -66.7% |
| Q3 2023 | $82,210 | +619.5% | 17,163 | +929.0% | 0.00% | – |
| Q2 2023 | $11,426 | +63377.8% | 1,668 | -28.8% | 0.00% | -100.0% |
| Q1 2023 | $18 | +63.6% | 2,344 | +61.0% | 0.00% | – |
| Q4 2022 | $11 | -100.0% | 1,456 | -90.2% | 0.00% | -100.0% |
| Q3 2022 | $121,000 | +72.9% | 14,820 | +104.6% | 0.00% | 0.0% |
| Q2 2022 | $70,000 | +89.2% | 7,245 | +177.1% | 0.00% | – |
| Q1 2022 | $37,000 | +311.1% | 2,615 | +471.0% | 0.00% | – |
| Q4 2021 | $9,000 | -71.0% | 458 | -66.9% | 0.00% | -100.0% |
| Q3 2021 | $31,000 | +244.4% | 1,385 | +246.2% | 0.00% | – |
| Q2 2021 | $9,000 | – | 400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,472,331 | $32,804,000 | 6.54% |
| Cormorant Asset Management, LP | 3,102,199 | $67,957,000 | 2.76% |
| NEA Management Company, LLC | 7,703,205 | $171,627,000 | 2.04% |
| Avoro Capital Advisors LLC | 3,311,434 | $61,003,000 | 0.96% |
| Octagon Capital Advisors LP | 150,000 | $3,342,000 | 0.82% |
| Alphabet Inc. | 1,464,015 | $32,618,000 | 0.77% |
| Casdin Capital, LLC | 960,883 | $21,408,000 | 0.53% |
| RTW INVESTMENTS, LP | 1,214,572 | $26,005,000 | 0.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 119,647 | $2,666,000 | 0.22% |
| Avidity Partners Management LP | 300,000 | $6,684,000 | 0.15% |